What is the highest possible stock price for Synthetic Biologics?
On average, they expect Synthetic Biologics' stock price to reach $2.50 in the next year. This suggests a possible upside of 682.7% from the stock's current price. View analysts' price targets for Synthetic Biologics or view top-rated stocks among Wall Street analysts. Who are Synthetic Biologics' key executives?
Who sold Synopsys Inc (SNPs) stock?
Chairman of the Board & Co-CEO of Synopsys Inc (30-Year Financial, Insider Trades) Geus Aart De (insider trades) sold 226,958 shares of SNPS on 12/10/2021 at an average price of $360.11 a share. Synopsys enjoys a leadership position in the EDA space, which has helped it develop strong relationships with chip designers, enhancing switching costs.
How much of Synopsys stock are insiders buying or selling?
In the past three months, Synopsys insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $85,114,661.00 in company stock. Only 1.56% of the stock of Synopsys is held by insiders. 84.32% of the stock of Synopsys is held by institutions.
Do analysts agree on Synopsys'(snpsy) stock's price target?
According to analysts' consensus price target of $375.64, Synopsys has a forecasted upside of 27.2% from its current price of $295.29. Synopsys has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Should I buy or sell Synthetic Biologics stock right now?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last twelve months. There are...
What is Synthetic Biologics' stock price forecast for 2022?
1 analysts have issued twelve-month price objectives for Synthetic Biologics' shares. Their forecasts range from $2.25 to $2.50. On average, they p...
How has Synthetic Biologics' stock performed in 2022?
Synthetic Biologics' stock was trading at $0.27 at the beginning of the year. Since then, SYN stock has decreased by 22.2% and is now trading at $0...
Are investors shorting Synthetic Biologics?
Synthetic Biologics saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 1,150,000 shares, a drop of...
When is Synthetic Biologics' next earnings date?
Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for...
How were Synthetic Biologics' earnings last quarter?
Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) announced its quarterly earnings results on Monday, May, 16th. The company reported ($0.03) earnings p...
When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?
Synthetic Biologics's stock reverse split on Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The numb...
Who are Synthetic Biologics' key executives?
Synthetic Biologics' management team includes the following people: Mr. Steven A. Shallcross CPA , CEO, CFO, Treasurer, Corp. Sec. & Director (A...
Who are some of Synthetic Biologics' key competitors?
Some companies that are related to Synthetic Biologics include Annexon (ANNX) , Pieris Pharmaceuticals (PIRS) , Wave Life Sciences (WVE) , Next...
When will Synopsys report results for 2021?
What is SNPS in Samsung?
Synopsys, Inc. (Nasdaq: SNPS) today announced it will report results for the third quarter fiscal year 2021 on Wednesday, Aug. 18, 2021, after the market close.
Is Synopsis repurchased?
Synopsys Inc (NASDAQ: SNPS) Synopsys Fusion Design Platform has enabled Samsung Electronics Co Ltd (OTC: SSNLF) Foundry to achieve first-pass silicon success for an advanced, high-performance, and multi-subsystem system-on-chip (SoC), validating the extended power, performance, and area (PPA) benefits of its next-generation, 3-nanometer (nm) gate-all-around (GAA) process technology. Samsung's latest, advanced 3nm GAA process has benefited from the extensive collaboration with Synopsys and the ac
When will Synthetic Biologics release results?
Synopsis, Inc. (SNPS) has signed an accelerated share repurchase agreement with Mizuho Markets Americas. Synopsis, a U.S.-based electronic design automation company, will repurchase its shares worth $175 million. Also, the company announced a collaboration with Samsung’s System LSI Business. According to the share repurchase agreement, Synopsys will buy back approximately 521,000 shares on or before August 18, 2021. The exact number of shares repurchased will depend on Synopsys’ weighted average
When is Synthetic Biologics earnings call 2021?
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2021 on Wednesday, May 5, 2021, and to host a conference call the same day at 4:30 p.m. ET. The dial-in information for the call is as follows:
What is synthetic biologics?
(AMEX:SYN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern Time.
When will synthetic biologics release earnings?
(NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today announced an amendment to the Company's option for an exclusive license with Massachusetts General Hospital ("MGH") ...
How many shares of synthetic biologics are there after the split?
Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Synthetic Biologics.
About Synopsys
An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.
Synopsys (NASDAQ:SNPS) Frequently Asked Questions
Synopsys, Inc. engages in the provision of software products and consulting services in the electronic design automation industry. It operates through the following segments: Semiconductor and System Design, and Software Integrity. The Semiconductor and System Design segment includes the EDA, IP and System Integration.
About Synovis Life Technologies
10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synopsys in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock.
0.0 Analyst's Opinion
Synovis Life Technologies, Inc. (Synovis) is a medical device company. The Company develops, manufactures and markets biological and mechanical products used by several surgical specialties to facilitate the repair and reconstruction of soft tissue damaged or destroyed by disease or injury.
What is Synovis Life Technologies' stock symbol?
Synovis Life Technologies has received 66 “outperform” votes. (Add your “outperform” vote.)
Where are Synovis Life Technologies' headquarters?
Synovis Life Technologies trades on the NASDAQ under the ticker symbol "SYNO."
How can I contact Synovis Life Technologies?
Synovis Life Technologies is headquartered at 2575 University Ave W, SAINT PAUL, MN 55114-1024, United States.
When will Synaptics report financial results?
Synovis Life Technologies' mailing address is 2575 University Ave W, SAINT PAUL, MN 55114-1024, United States. The medical device company can be reached via phone at +1-651-7967300.
Is Synaptics a 5G company?
SAN JOSE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: SYNA) today announced that it will report financial results for the fourth quarter of fiscal 2021 on Thursday, August 5, 2021 after the close of market.
Is Synaptics stock on fire?
Synaptics (NASDAQ: SYNA) is in a solid position to take advantage of the proliferation of 5G networks and devices , as well as sitting on a few other growth drivers.
Fullgent Genetics (FLGT) Q4 Earnings and Revenues Surpass Estimates
Synaptics ( NASDAQ: SYNA) stock has been on fire on the market over the past six months thanks to solid growth across the Internet of Things (IoT), personal computer (PC), and mobile businesses, and the company's latest quarterly report indicates that its rally could get stronger. Synaptics also delivered solid guidance for the current quarter. Let's look at the factors driving Synaptics' impressive growth and find out why the stock could jump higher after a strong performance so far in 2021.
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time
Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 25.56% and 31.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sensonics: Despite FDA Approval, Expectations Are Too High, Says Raymond James
GERMANTOWN, Md., February 15, 2022--Senseonics Holdings, Inc.
